I've heard that these are smaller and easier to mass produce than antibodies, which are difficult to produce. That is one reason why Humira costs so much. They should also better penetrate the tissues, but they do have a much shorter half-life and I would worry about serum sickness. Interesting more for the future than COVID19 IMO.
View: https://twitter.com/Reuters/status/1258105499611877376
A news story (again translated):
Human interaction with bats has burdened us with a new coronavirus. The remedy may come from a llama and, indirectly, from a Flemish professor with stubborn students and a supply of dromedary blood. Xavier Saelens has little time, because he will soon be on Canadian radio. The researcher at UGent and the Flemish Institute for Biotechnology (VIB) will explain how a Flemish llama currently has antibodies in her blood against the coronavirus sars-CoV-2 and how that could lead to a medicine against the fatal lung disease covid-19.
The llama is four years old, is called Winter and lives with 130 peers on a farm in Antwerp. In a study conducted by Saelens with colleagues from Texas, the llama was brought into contact with proteins from sars and mers viruses, so that she would produce antibodies against it. The antibodies in blood Winters prove now presumably be suitable to a similar virus that did not exist when the study began, the new coronavirus that human slaughter since the end of 2019 makes sacrifices Saelens hopes to warn against rushing euphoria. It will be months before the Winter antibodies can be tested on humans. The road to a usable medicine is even longer, dotted with obstacles and perhaps dead.
Antibodies are proteins produced by an immune system to, for example, defuse a virus. They do this by attaching themselves to the tentacles that the virus uses to enter cells. It is not uncommon for human medicines to be based on such antibodies. But why would a researcher work with antibodies from llamas if he can also do this with smaller, more handy animals? This is an indirect consequence of a difficult course at the faculty of biology of the VUB in 1989.
Sleeping sickness
That lab was led by Professor Raymond Hamers, who asked his students to isolate antibodies from blood. His then assistant, Serge Muyldermans, still happily tells that story. 'The idea was that the students would isolate antibodies from the blood of a human volunteer, which was then still possible. But the students refused, because they were afraid of becoming infected with HIV or hepatitis. We understood that. We suggested killing a mouse and using that blood, but they also found it unethical. We were pissed. It seemed as if they just wanted to avoid doing the practical. Fortunately, we still had blood from a dromedary from Mali in the refrigerator, the remainder of an investigation into sleeping sickness. The students could think of no objections and went to work, but the antibodies they found were much smaller than the animal antibodies we knew. It is to the credit of Hamers that he did not see that as a failure, but went to work with it. That characterizes him. He was interested in everything. That's why it was so nice to work for him. You could do anything you suggested. "
Raymond Hamers soon saw that certain camelid antibodies, such as the dromedary, are smaller because they consist of only one protein, while the antibodies of other complex animals, such as humans and mice, are a combination of two different proteins. That seemed absurd, but Hamers soon saw the benefits. Smaller antibodies can reach places on the surface of a virus where larger ones can be difficult . The fact that an active antibody can be made from one molecule, rather than a combination of two, also seemed to facilitate the reproduction of antibodies in laboratories.
It took hard work and a lot of extra investment to prove those suspicions. Because smaller antibodies were first discovered in a dromedary, the researchers initially went to great lengths to get more dromedary blood. It took them a while to realize that the size and character of llamas made them slightly easier to work with.
Ablynx
It took much longer before the technique could lead to a useful drug. To do that, Hamers, Muyldermans and a few others founded a company in 2004, Ablynx, which still exists today and has around 450 employees, but no longer as an independent company. Antibodies made by llamas are reproduced by Ablynx through genetically modified yeast cells, making it much easier to produce large amounts. Because the first patents on the insights of Raymond Hamers have expired, other companies and institutions are also working with antibodies from llamas. Ablynx is not involved in the research of Xavier Saelens and his colleagues. In 2018, when it was about to make the first useful drug from llama antibodies against a blood disorder, Ablynx was bought for € 3.9 billion by the French pharmaceutical group Sanofi (Dromedary leads to billions of dollars, DS February 3, 2018) .
Ablynx still has more than a hundred laboratory animals. Half of them are llamas, the others are alpacas, which look like llamas but are smaller. That makes them even easier to handle. Carlo Boutton, who works with the animals at Ablynx, emphasizes that the tests are not particularly painful or harmful. He compares the pain of inserting a virus with the pain a person feels when he gets a flu shot. Blood samples then follow. The animals are only used for a few years. After that, they are not killed, like most lab animals, but placed in a herd of 'retired' animals. Since 2017, they have been given up for adoption to people whose ability to care for the animals has been assessed in advance.
According to several researchers who have worked closely with him, the chances of a discovery such as that of Professor Hamers have decreased today. Jan Steyaert, who was involved in the founding of Ablynx, still teaches at the VUB and has also started several other companies, says Hamers' success demonstrates the value of 'fundamental research initiated by the researcher'. 'Researchers have less and less time for this, because the funding of their research often depends on well-defined results. That's not a good thing for accidental discoveries. ”
Serge Muyldermans agrees. The success of the lamas antibodies can also be seen as an anthropocentric argument for the conservation of biodiversity. Animal species that become extinct due to human activity may also have special properties that can eventually lead to medicines against deadly human diseases. Finally, you can also read the 1989 practical story as a plea for empowered students and resourceful professors. If Hamers' students had been more accommodating, he might have missed the discovery of his life.